Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod...
Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024...
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET –...
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax...
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its...
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease...
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to...
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E...
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early...
Abivax presents first-half 2024 financial results Cash balance of EUR 222M at June 30, 2024; cash runway in to...
Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating...
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately...
PARIS, France, June 4, 2024 – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a...
ABIVAX assure la découverte préliminaire de candidats médicaments pour le traitement d’infections virales majeures Evotec optimise les...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관